Fig. 6. Safety assessment in cynomolgus monkey.

Slides:

Advertisements

Similar presentations

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Advertisements

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 3. Structure of ALS-associated RNA binding proteins.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 1. NASH and fibrosis develop late in mice fed an HFD.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Bone tissue formation within the Ti-mesh channels.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 1. Working principle of the plasmon sensor chip (NPS) for tEVs.

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 2 Systemically released inflammatory factors directly affect HSC-e cell fate. Systemically released inflammatory factors directly affect HSC-e cell.

Fig. 8. Therapeutic effects of the transplantation of hiPSC-EPO–producing cells on renal anemia in adenine-treated mice. Therapeutic effects of the transplantation.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Type 1 immunity drives metabolic disease but protects against NAFLD

Fig. 5. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. Serum VEGF-C correlates.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 2. Vascular inflammation blocks perivascular adipocyte differentiation through paracrine signals. Vascular inflammation blocks perivascular adipocyte.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 4 Nanocages captured multiple TB-related analytes.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Fig. 1. Experimental workflow of the dAST method and computationally estimated operational space. Experimental workflow of the dAST method and computationally.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 6. CXM correlates with age and growth velocity.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Analysis of the bacterial nidus within tissue abscesses by MALDI IMS demonstrates a paucity of calprotectin signal. Analysis of the bacterial nidus.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 7. Scale-up of AAV vector–mediated liver gene transfer of secretable GAA to nonhuman primates. Scale-up of AAV vector–mediated liver gene transfer.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 8. Zbtb7a deficiency impairs antigen presentation by AMs.

Fig. 1 Study design and antibody pharmacokinetics.

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors by Takahiro Ishiguro, Yuji Sano, Shun-ichiro Komatsu, Mika.

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs

Presentation transcript:

Fig. 6. Safety assessment in cynomolgus monkey. Safety assessment in cynomolgus monkey. (A) Binding affinity of ERY974 to human or cynomolgus monkey epitope peptides derived from GPC3 or CD3 was measured by surface plasmon resonance analysis. KD, dissociation constant. (B) Change in serum interleukin (IL)–6 concentration over time in a single-dose study. Five animals per sex per group received a single administration of ERY974. Necropsies were performed on day 22 after the dose. (C) Serum IL-6 concentration (red and black lines) over time in a repeated-dose study. Three animals per sex received doses (blue bars) that increased daily by about threefold to 1.5 mg/kg. Necropsies were performed on day 10. Takahiro Ishiguro et al., Sci Transl Med 2017;9:eaal4291 Published by AAAS